Ferritin/alanine aminotransferase ratio as a possible marker for predicting the prognosis of acute liver injury

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 8, 2011, Pages 1326-1332

  Ozawa, Eisuke ^a,b   Abiru, Seigo ^a   Nagaoka, Shinya ^a   Yano, Koji ^a   Komori, Atsumasa ^a   Migita, Kiyoshi ^a   Yatsuhashi, Hiroshi ^a   Taura, Naota ^b   Ichikawa, Tatsuki ^b   Ishibashi, Hiromi ^a   Nakao, Kazuhiko ^b  

^a NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

Acute liver failure; Ferritin; Heme oxygenase 1 (HO 1); Prognostic predictor

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOCHEMICAL MARKER; BIOLOGICAL MARKER; FERRITIN; HEME OXYGENASE 1; HISTAMINE H2 RECEPTOR ANTAGONIST; MANNITOL;

ACUTE HEPATITIS; ACUTE LIVER INJURY; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD CHEMISTRY; BLOOD SAMPLING; BRAIN EDEMA; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; EXTRACORPOREAL CIRCULATION; FEMALE; FERRITIN BLOOD LEVEL; FULMINANT HEPATIC FAILURE; HEPATITIS; HEPATITIS A; HEPATITIS B; HOSPITAL ADMISSION; HUMAN; INJURY SEVERITY; LABORATORY TEST; LIVER INJURY; LIVER TRANSPLANTATION; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL SUPPORT; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEVERE ACUTE HEPATITIS; SURVIVOR; TREATMENT OUTCOME;

EID: 79960468847     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06743.x     Document Type: Article

References (33)

1. Tsutsui H, Adachi K, Seki E, Nakanishi K. Cytokine-induced inflammatory liver injuries. Curr. Mol. Med. 2003; 3: 545-9.
2. Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000; 32: 734-9.
3. James B, Alan R. Glucocorticoid suppression of macrophage migration inhibitory factor. J. Exp. Med. 1973; 137: 1031-41.
4. Nagaki M, Iwai H, Naiki T, Ohnishi H, Muto Y, Moriwaki H. High levels of serum interleukin-10 and tumor necrosis factor-alpha are associated with fatality in fulminant hepatitis. J. Infect. Dis. 2000; 182: 1103-8.
5. Hiraoka A, Horiike N, Akbar SM, Michitaka K, Matsuyama T, Onji M. Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure. J. Gastroenterol. 2005; 40: 52-6.
6. Mita A, Hashikura Y, Tagawa Y, Nakayama J, Kawakubo M, Miyagawa S. Expression of Fas ligand by hepatic macrophages in patients with fulminant hepatic failure. Am. J. Gastroenterol. 2005; 100: 2551-9.
7. Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood 2002; 99: 3505-16.
8. Esumi N, Ikushima S, Hibi S, Todo S, Imashuku S. High serum ferritin level as a marker of malignant histiocytosis and virus-associated hemophagocytic syndrome. Cancer 1988; 61: 2071-6.
9. Ota T, Higashi S, Suzuki H, Eto S. Increased serum ferritin levels in adult Still's disease. Lancet 1987; 1: 562-3.
10. Maines MD. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J. 1988; 2: 2557-68.
11. Morse D, Choi AM. Heme oxygenase-1: the 'emerging molecule' has arrived. Am. J. Respir. Cell Mol. Biol. 2002; 27: 8-16.
12. Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc. Natl. Acad. Sci. USA 1968; 61: 748-55.
13. Schaer DJ, Schaer CA, Schoedon G, Imhof A, Kurrer MO. Hemophagocytic macrophages constitute a major compartment of heme oxygenase expression in sepsis. Eur. J. Haematol. 2006; 77: 432-6.
14. Kirino Y, Takeno M, Iwasaki M. Increased serum HO-1 in hemophagocytic syndrome and adult-onset Still's disease: use in the differential diagnosis of hyperferritinemia. Arthritis Res. Ther. 2005; 7: R616-24.
15. Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem. Biophys. Res. Commun. 1984; 122: 1450-9.
16. Tsubouchi H, Hirono S, Gohda E etal. Clinical significance of human hepatocyte growth factor in blood from patients with fulminant hepatic failure. Hepatology 1989; 9: 875-81.
17. Shiota G, Okano J, Kawasaki H, Kawamoto T. Serum hepatocyte growth factor levels in liver disease: clinical implications. Hepatology 1995; 21: 106-12.
18. Ido A, Tsubouchi H. Translational research to identify clinical applications of hepatocyte growth factor. Hepatol. Res. 2009; 39: 739-47.
19. Jalan R. Gc-globulin to predict outcome in acute liver failure: a panacea? Liver Transpl. 2005; 11: 1169-71.
20. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97: 439-45.
21. Anand AC, Nightingale P, Neuberger JM. Early indicators of prognosis in fulminant hepatic failure: an assessment of the King's criteria. J. Hepatol. 1997; 26: 62-8.
22. Trey C, Davidson CS. The management of fulminate hepatic failure. Prog. Liver Dis. 1970; 3: 282-98.
23. Eastham EJ, Bell JI, Douglas AP. Serum ferritin levels in acute hepatocellular damage from paracetamol overdosage. Br. Med. J. 1976; 1: 750-1.
24. Prieto J, Barry M, Sherlock S. Serum ferritin in patients with iron overload and with acute and chronic liver diseases. Gastroenterology 1975; 68: 525-33.
25. Kawashima R, Mochida S, Matsui A etal. Expression of osteopontin in Kupffer cells and hepatic macrophages and stellate cells in rat liver after carbon tetrachloride intoxication: a possible factor for macrophage migration into hepatic necrotic areas. Biochem. Biophys. Res. Commun. 1999; 256: 527-31.
26. Moestrup SK, Moller HJ. CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann. Med. 2004; 36: 347-54.
27. Hiraoka A, Horiike N, Akbar SM, Michitaka K, Matsuyama T, Onji M. Expression of CD163 in the liver of patients with viral hepatitis. Pathol. Res. Pract. 2005; 201: 379-84.
28. Moller HJ, Gronbaek H, Schiodt FV etal. Soluble CD163 from activated macrophages predicts mortality in acute liver failure. J. Hepatol. 2007; 47: 671-6.
29. Porcheray F, Viaud S, Rimaniol AC etal. Macrophage activation switching: an asset for the resolution of inflammation. Clin. Exp. Immunol. 2005; 142: 481-9.
30. Nakahira K, Takahashi T, Shimizu H etal. Protective role of heme oxygenase-1 induction in carbon tetrachloride-induced hepatotoxicity. Biochem. Pharmacol. 2003; 66: 1091-105.
31. Milman N, Graudal N. Serum ferritin in acute viral hepatitis. Scand. J. Gastroenterol. 1984; 19: 38-40.
32. Fardet L, Coppo P, Kettaneh A, Dehoux M, Cabane J, Lambotte O. Low glycosylated ferritin, a good marker for the diagnosis of hemophagocytic syndrome. Arthritis Rheum. 2008; 58: 1521-7.
33. Vignes S, Le Moel G, Fautrel B, Wechsler B, Godeau P, Piette JC. Percentage of glycosylated serum ferritin remains low throughout the course of adult onset Still's disease. Ann. Rheum. Dis. 2000; 59: 347-50.